secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-040656
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax appoints Charles W. Newton to Board, increasing size to nine members
----------------------------------------------------------------------------

- Board expanded from 8 to 9 members; Charles W. Newton appointed as Class III director effective April 25, 2025.
- Newton receives initial equity grant of 42,840 stock options and 28,560 RSUs ($525,000 grant-date fair value).
- Annual equity grants valued at $350,000 will begin after the 2026 Q2 board meeting.
- Board affirms Newton qualifies as independent under Nasdaq standards; no related-party transactions.
- Standard indemnification agreement to be entered with Novavax.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925040656/0001104659-25-040656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925040656/tm2513372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-040656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer